Regulatory
Pfizer’s Talzenna (talazoparib) Receives European Commission Approval for Germline BRCA-Mutated
Shots: The approval is based on P-III EMBRACA study results assessing Talzenna (qd, 1mg) vs CT (capecitabine/eribulin/gemcitabine/vinorelbine) in 431 patients in ratio (2:1) with inherited BRCA1/2 mutation & LA or […]readmore
